Predictive validity and immune cell involvement in the pathogenesis of piroxicam-accelerated colitis in interleukin-10 knockout mice

International Immunopharmacology

Volumn 21, Issue 1, 2014, Pages 137-147

  Holgersen, Kristine ^a,b   Kvist, Peter Helding ^a   Hansen, Axel Kornerup ^b   Holm, Thomas Lindebo ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Inflammatory bowel disease; Inflammatory mediators; Interleukin 10 knockout mouse; Piroxicam; Validity

Indexed keywords

ABATACEPT; CALGRANULIN; CD8 ANTIGEN; CLODRONIC ACID; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; MONOCLONAL ANTIBODY; PIROXICAM; PREDNISOLONE; BLOCKING ANTIBODY; CYCLOSPORIN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTESTINE FLORA; MOUSE; NONHUMAN; PATHOGENESIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; STIMULATION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; ENTEROCOLITIS; EVALUATION STUDY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE DEPLETION; MACROPHAGE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BLOCKING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYCLOSPORINE; ENTEROCOLITIS; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; LYMPHOCYTE DEPLETION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; PIROXICAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901001159     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.04.017     Document Type: Article

References (56)

1. R.B. Sartor Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis Nat Clin Pract Gastroenterol Hepatol 3 2006 390 407
2. D.C. Baumgart, and S.R. Carding Inflammatory bowel disease: cause and immunobiology Lancet 369 2007 1627 1640
3. J. Matricon, N. Barnich, and D. Ardid Immunopathogenesis of inflammatory bowel disease Self Nonself 1 2010 299 309
4. I. Ordas, L. Eckmann, M. Talamini, D.C. Baumgart, and W.J. Sandborn Ulcerative colitis Lancet 380 2012 1606 1619
5. D.C. Baumgart, and W.J. Sandborn Crohn's disease Lancet 380 2012 1590 1605
6. K.T. Thia, W.J. Sandborn, W.S. Harmsen, A.R. Zinsmeister, and E.V. Loftus Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort Gastroenterology 139 2010 1147 1155
7. D.C. Baumgart, and W.J. Sandborn Inflammatory bowel disease: clinical aspects and established and evolving therapies Lancet 369 2007 1641 1657
8. T. Dassopoulos, S. Sultan, Y.T. Falck-Ytter, J.M. Inadomi, and S.B. Hanauer American Gastroenterological Association Institute Technical Review on the use of thiopurines, methotrexate, and anti-TNFα biologic drugs for the induction and maintenance of remission in inflammatory Crohn's Disease Gastroenterology 145 2013 1464 1478
9. S. Ardizzone, A. Cassinotti, and R. de Franchis Immunosuppressive and biologic therapy for ulcerative colitis Expert Opin Emerg Drugs 17 2012 449 467
10. C.N. Bernstein, and F. Shanahan Selected summary: Feagan BG, McDonald JWD, Rochon J, et al. for the Canadian Crohn's Relapse Prevention Trial Investigators. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330:1846-1851 (June) Gastroenterology 108 1995 943 945
11. L.E. Targownik, and C.N. Bernstein Infectious and malignant complications of TNF inhibitor therapy in IBD Am J Gastroenterol 108 2013 1835 1842
12. I.C. Solberg, I. Lygren, J. Jahnsen, E. Aadland, O. Høie, and M. Cvancarova et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) Scand J Gastroenterol 44 2009 431 440
13. L. Peyrin-Biroulet, E.V. Loftus Jr., J.F. Colombel, and W.J. Sandborn The natural history of adult Crohn's disease in population-based cohorts Am J Gastroenterol 105 2010 289 297
14. D.J. Berg, J. Zhang, J.V. Weinstock, H.F. Ismail, K.A. Earle, and H. Alila et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice Gastroenterology 123 2002 1527 1542
15. K. Holgersen, P.H. Kvist, H. Markholst, A.K. Hansen, and T.L. Holm Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse - a model mimicking inflammatory bowel disease J Crohns Colitis 8 2014 147 160
16. L.P. Hale, M.R. Gottfried, and A. Swidsinski Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria Inflamm Bowel Dis 11 2005 1060 1069
17. M. Chichlowski, and L.P. Hale Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad Am J Physiol Gastrointest Liver Physiol 295 2008 G1139 G1149
18. W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, and S. Katz et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
19. W.J. Sandborn, C. Gasink, L.L. Gao, M.A. Blank, J. Johanns, and C. Guzzo et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease N Engl J Med 367 2012 1519 1528
20. M. Chichlowski, J.M. Sharp, D.A. Vanderford, M.H. Myles, and L.P. Hale Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice Comp Med 58 2008 534 541
21. J.B. Brown, G. Lee, G.R. Grimm, and T.A. Barrett Therapeutic benefit of pentostatin in severe IL-10 -/- colitis Inflamm Bowel Dis 14 2008 880 887
22. L.P. Hale, P.K. Greer, C.T. Trinh, and M.R. Gottfried Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease Clin Immunol 116 2005 135 142
23. W. Nicklas, P. Baneux, R. Boot, T. Decelle, A.A. Deeny, and M. Fumanelli et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units Lab Anim 36 2002 20 42
24. S.N.S. Murthy, H.S. Cooper, H. Shim, R.S. Shah, S.A. Ibrahim, and D.J. Sedergran Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin Dig Dis Sci 38 1993 1722 1734
25. H.T. Lindebo, S.S. Poulsen, H. Markholst, and S. Reedtz-Runge Pharmacological evaluation of the SCID T cell transfer model of colitis: as a model of Crohn's disease Int J Inflamm 2012 412178
26. T. Sha, K. Igaki, M. Yamasaki, T. Watanabe, and N. Tsuchimori Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice Int Immunopharmacol 15 2013 23 29
27. H. Sann, J. Erichsen, M. Hessmann, A. Pahl, and A. Hoffmeyer Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice Life Sci 92 2013 708 718
28. T. Scheinin, D.M. Butler, F. Salway, B. Scallon, and M. Feldmann Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis Clin Exp Immunol 133 2003 38 43
29. S. Solomon, N. Rajasekaran, E. Jeisy-Walder, S.B. Snapper, and H. Illges A crucial role for macrophages in the pathology of K/BxN serum-induced arthritis Eur J Immunol 35 2005 3064 3073
30. A. Bleich, M. Mahler, C. Most, E.H. Leiter, E. Liebler-Tenorio, and C.O. Elson et al. Refined histopathologic scoring system improves power to detect colitis QTL in mice Mamm Genome 15 2004 865 871
31. N.N. Gorgani, Y. Ma, and H.F. Clark Gene signatures reflect the marked heterogeneity of tissue-resident macrophages Immunol Cell Biol 86 2007 246 254
32. J.L. Parker, and K.J. Clare The success rate of new drug development in clinical trials: Crohn's disease J Pharm Pharm Sci 13 2010 191 197
33. E. Burri, and C. Beglinger The use of fecal calprotectin as a biomarker in gastrointestinal disease Expert Rev Gastroenterol Hepatol 8 2014 197 210
34. W.A. Faubion Jr., J.G. Fletcher, S. O'Byrne, B.G. Feagan, W.J. de Villiers, and B. Salzberg et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging Am J Gastroenterol 108 2013 1891 1900
35. M.F. Neurath New targets for mucosal healing and therapy in inflammatory bowel diseases Mucosal Immunol 7 2014 6 19
36. N.J. Davidson, S.A. Hudak, R.E. Lesley, S. Menon, M.W. Leach, and D.M. Rennick IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice J Immunol 161 1998 3143 3149
37. I.C. Roberts-Thomson, J. Fon, W. Uylaki, A.G. Cummins, and S. Barry Cells, cytokines and inflammatory bowel disease: a clinical perspective Expert Rev Gastroenterol Hepatol 5 2011 703 716
38. P. Miossec, T. Korn, and V.K. Kuchroo Interleukin-17 and type 17 helper T cells N Engl J Med 361 2009 888 898
39. C. Becker, S. Wirtz, and M.F. Neurath Stepwise regulation of TH1 responses in autoimmunity: IL-12-related cytokines and their receptors Inflamm Bowel Dis 11 2005 755 764
40. D.A.A. Vignali, and V.K. Kuchroo IL-12 family cytokines: immunological playmakers Nat Immunol 13 2012 722 728
41. A.C. Ford, W.J. Sandborn, K.J. Khan, S.B. Hanauer, N.J. Talley, and P. Moayyedi Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 644 659
42. Y. Ikenoue, T. Tagami, and M. Murata Development and validation of a novel IL-10 deficient cell transfer model for colitis Int Immunopharmacol 5 2005 993 1006
43. J. Kountouras, C. Zavos, and D. Chatzopoulos Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease J Cell Mol Med 8 2004 317 328
44. A.C. Ford, C.N. Bernstein, K.J. Khan, M.T. Abreu, J.K. Marshall, and N.J. Talley et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 590 599
45. L.A. Zenewicz, A. Antov, and R.A. Flavell CD4 T-cell differentiation and inflammatory bowel disease Trends Mol Med 15 2009 199 207
46. J.J. O'Shea, and W.E. Paul Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells Science 327 2010 1098 1102
47. M. Barry, and R.C. Bleackley Cytotoxic T lymphocytes: all roads lead to death Nat Rev Immunol 2 2002 401 409
48. W.G. Morice The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders Am J Clin Pathol 127 2007 881 886
49. K. Sato, K. Ohtsuka, H. Watanabe, H. Asakura, and T. Abo Detailed characterization of gamma delta T cells within the organs in mice: classification into three groups Immunology 80 1993 380 387
50. P.D. Smith, T.T. MacDonald, and R.S. Blumberg Intraepithelial lymphocytes: unusual T cells at epithelial surfaces Principles of Mucosal Immunology 2013 Garland Science 69 86
51. S. Danese New therapies for inflammatory bowel disease: from the bench to the bedside Gut 61 2012 918 932
52. N. van Rooijen, and E. Hendrikx Liposomes for specific depletion of macrophages from organs and tissues Methods Mol Biol 605 2010 189 203
53. A.M. Mowat, and C.C. Bain Mucosal macrophages in intestinal homeostasis and inflammation J Innate Immun 3 2011 550 564
54. J.E. Qualls, A.M. Kaplan, N. van Rooijen, and D.A. Cohen Suppression of experimental colitis by intestinal mononuclear phagocytes J Leukoc Biol 80 2006 802 815
55. N. Watanabe, K. Ikuta, K. Okazaki, H. Nakase, Y. Tabata, and M. Matsuura et al. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice Dig Dis Sci 48 2003 408 414
56. C.C. Bain, C.L. Scott, H. Uronen-Hansson, S. Gudjonsson, O. Jansson, and O. Grip et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors Mucosal Immunol 6 2013 498 510